The American Cancer Society, the largest non-government, not-for-profit funding source of cancer research in the United States, has approved funding of a new research grant totaling $792,000 to a researcher at Yale University.
SBP researcher Ranjan Perera uncovered the M.O. of a mysterious lncRNA molecule called SPRIGHTLY that acts as a hub for cancer-related genes in the nucleus. The study identified “major” RNA binding partners – genes already implicated in a variety of cancers. In a mouse model of melanoma, tumors with reduced SPRIGHTLY grew more slowly, indicating use as a therapeutic target or biomarker. Science Advances.
On Monday, the Yale School of Medicine, partnering with Yale New Haven Hospital, took the next step toward personalized medicine, cutting the ribbon on its Center for Genome Analysis on Yale’s West Campus.
Some types of sarcomas elicit a greater immune response than others, which sheds light on how immunotherapy could be used for this connective-tissue cancer, according to a new study in Cancer. Photos, video available: http://www.fredhutch.org/en/news/media-relations/bios-photos/pollack-seth.html
Seattle Cancer Care Alliance (SCCA) is thrilled to welcome Dr. Theresa M. McDonnell as the Alliance’s new Chief Nurse Executive, Vice President of Clinical Operations. She will be responsible for overseeing all nursing staff, guiding patient care delivery, ensuring staff accountability for providing a patient-centered clinical practice environment, and overseeing general clinical quality and patient safety.
A shorter course of radiation therapy given to breast cancer patients following mastectomy is safe and effective and cuts treatment time in half. That is according to data from a phase II clinical trial conducted by Rutgers Cancer Institute of New Jersey investigators and other colleagues who examined a hypofractionated regimen given over three weeks versus the traditional six week course of treatment.
This week at the ONS 42nd Annual Congress, experts from The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins present results of a patient safety initiative to administer vincristine via IV mini-bag, rather than syringe, echoing NCCN’s Just Bag It Campaign.
Navigating a treatment path for cancer can be challenging for many patients, especially coordination of appointments between multiple practitioners. Combine that with a wealth of information about the disease which may not be easy to understand and there exists the potential for poor health outcomes. Nurses at Rutgers Cancer Institute of New Jersey explored both topics in order to further enhance the patient experience. Their findings are being presented as part of a poster session at the Oncology Nursing Society’s Annual Congress being held this week.
The American Association for Cancer Research, or AACR, announced that Seattle Cancer Care Alliance’s Dr. Nancy Davidson, an internationally acclaimed breast cancer oncologist, is among its newly elected class of Fellows of the AACR Academy.
Radiotherapy alone is often used to treat early-stage glottic cancer (ESGC), a cancer of the vocal chords, however, the optimal radiation treatment schedule remains unknown, until now.
Patients who expressed the tumor antigen NY-ESO-1 had more aggressive cancers and were more likely to die early from their disease, according to a large study conducted by Roswell Park Cancer Institute researchers and published online ahead of print in the journal Gynecologic Oncology.
The University of Texas MD Anderson Children’s Cancer Hospital joins Houston restaurants and businesses to host its second annual Prom Party Palooza, a prom for teen cancer patients and their families. The glamorous night takes place at MD Anderson on Saturday, April 29 from 6 to 9 p.m.
A biopolymer structure enriched with nutrients shows how immunotherapy could be adapted for solid tumors, according to study in The Journal of Clinical Investigation.
Second cancers in children and adolescents and young adults (AYA) are far deadlier than they are in older adults and may partially account for the relatively poor outcomes of cancer patients ages 15-39 overall, a new study by UC Davis researchers has found."Second Primary Malignant Neoplasms and Survival in Adolescent and Adult Cancer Survivors" is published today in JAMA Oncology.
An early round of clinical testing shows that users of Opdivo, a drug sanctioned for treatment of small-cell lung cancer, more than tripled their five-year survival rate beyond the statistical average.
After studying viruses for 15 years, Dr. Anthony van den Pol believes he has found one that can safely and effectively kill chemotherapy-resistant ovarian cancer.
The NCCN Radiation Therapy Compendium™, launched in March 2017, provides a single access point for radiation therapy recommendations within 33 NCCN Guidelines®.
Select breast cancer patients who achieved pathologic complete response (pCR) after chemotherapy may be able to avoid follow-up breast and lymph node, or axillary, surgery, according to new findings from researchers at The University of Texas MD Anderson Cancer Center. The study, published today in JAMA Surgery, identifies the exceptional responders who are at lowest risk for local metastases and thereby are candidates for less invasive treatment options.
Small trial uses chloroquine to nix the process of "autophagy" that some cancer cells use to resist treatment, resensitzing glioblastoma to targeted therapy
Oncology community professionals are concerned about the ability of their patients to access cancer screening and treatment under the proposed American Health Care Act, according to a survey conducted March 23–25, 2017 at the National Comprehensive Cancer Network® (NCCN®) 22nd Annual Conference: Improving the Quality, Effectiveness, and Efficiency of Cancer Care™ at the Rosen Shingle Creek in Orlando, Florida.
The University of Texas MD Anderson Cancer Center and Lion Biotechnologies, Inc., a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced a multi-year strategic alliance agreement involving multi-arm clinical trials to evaluate the safety and efficacy of TIL therapy in ovarian, various sarcomas, and pancreatic cancers.
Karen Burns White, Deputy Associate Director of Dana-Farber/Harvard Cancer Center’s (DF/HCC) Initiative to Eliminate Cancer Disparities (IECD) since 2001, has been honored by the Massachusetts Medical Society as the 2017 recipient of the society’s Reducing Health Disparities Award. The honor recognizes an individual who has made outstanding contributions to reducing health disparities due to race, socioeconomic status, age, education, or sexual orientation.
Dana-Farber Cancer Institute has been recognized as a “Top 100 Great Hospital in America” by Becker's Hospital Review.
The Global Health Catalyst Cancer Summit is an annual event that provides a forum for global health stakeholders to network, share knowledge and strengthen high-impact international collaborations that save lives while reducing global health disparities. Participants at the GHC Summit come from all across North America, Europe, Africa, and other impacted nations. Participants include leaders from the World Health Organization, World Bank Group, policy makers, Diaspora organizations, community leaders, U.S. congressional representatives, internationally recognized physicians and researchers, industry, professional sports celebrities and other cancer advocates.
For the fifth time in five years, Dana-Farber Cancer Institute has been recognized as a leader in LGBTQ Healthcare Equity by the Human Rights Campaign (HRC) Foundation. The distinction is achieved through evaluation by the Healthcare Equality Index (HEI), an annual survey that measures inclusive policies and practices related to LGBT patients, visitors, and staff at nearly 600 medical facilities nationwide.
During this National Minority Health Month, there is a focus on bridging health equity in our communities including ensuring minority populations have access to high quality cancer screenings and treatments, adequate insurance coverage and other services. Health disparities researcher Jennifer Tsui, PhD of Rutgers Cancer Institute of New Jersey shares some insight.
Luis A. Diaz, MD, has been named the Head of the Division of Solid Tumor Oncology in the Department of Medicine at Memorial Sloan Kettering (MSK). An accomplished physician, pioneering researcher, and leader in the field of clinical oncology, Dr. Diaz most recently served as an associate professor of oncology at the Johns Hopkins University School of Medicine.
Study in Nature Nanotechnology describes new method to transform immune cells, while inside the body, into leukemia-fighting powerhouses
The third annual “Splash Away Cancer!” fundraising event takes place May 20, 2017. All proceeds support patient care and cancer research programs at The University of New Mexico Comprehensive Cancer Center.
Nonprofit cancer immunotherapy research organization hires pharmaceutical executive to lead its clinical trials program
New UC Project Finds Roadmap to Improve Patient Safety in Radiation Exposure
An international team of collaborators retroactively examined the associations between survival among patients diagnosed with invasive epithelial ovarian cancer and those patients’ history of hypertension, heart disease, diabetes, and medications taken for those conditions. They found that while hypertension was linked to better outcomes, diabetes was associated with decreased survival.
University of Colorado Cancer Center Study uncovers discrepant decision-making for use of 21-gene assay in women with cancer: • Testing occurs in high-risk population, despite current evidence • Non-concordance with NCCN Guidelines® recommendations • Racial and socio-economic disparities found in testing use
An international effort to analyze the entire database of Ebola virus genomes from the 2013-2016 West African epidemic reveals insights into factors that sped or slowed the rampage and calls for using real-time sequencing and data-sharing to contain future viral disease outbreaks.
Scientists at The Wistar Institute have unveiled part of the protein complex that protects telomeres—the ends of our chromosomes.
Celebrating all types of libraries during National Library Week (April 9 - 16), Rutgers Cancer Institute of New Jersey is recognizing its own patient resources at its specialized library.
A biochemical analysis study has discovered a new role for the DNA2 enzyme. The research, which was completed in the lab of Patrick Sung, professor of molecular biophysics and biochemistry at the Yale School of Medicine, looked at the way in which DNA2 repairs breaks in DNA that lead to the abnormalities that cause cancer.
The Lobos vs. Cancer Gala event, which celebrates its tenth year on Saturday, May 20, raises money for cancer research and treatment at UNM Cancer Center.
After 4-week trial of added rice bran, navy bean powder or neither, both the rice bran and navy bean groups showed increased dietary fiber, iron, zinc, thiamin, niacin, vitamin B6, folate, and alpha-tocopherol. The rice bran group also showed increased microbiome richness and diversity. When researchers treated colorectal cancer cells with stool extracts from these groups, they saw reduced cell growth from the groups that had increased rice bran and navy bean consumption.
Dr. Kristin Anderson from Fred Hutch will describe preclinical research on T-cell therapy showing how engineered T cells are able to kill both human and mouse ovarian cancer cells in the lab and significantly extend survival in a mouse model.
Oncora Medical, a precision radiation oncology software company, and The University of Texas MD Anderson Cancer Center, today announced a strategic alliance focusing on building the next generation of precision medicine software for radiation oncology.
Dana-Farber Cancer Institute scientists report a number of patients in a small study with RAS-driven lung, ovarian, and thyroid cancers got long-term clinical benefit from a combination of two drugs that targeted molecular pathways controlled by the RAS gene.
New Dana-Farber study shows patients with platinum resistant ovarian cancer who wouldn’t be expected to respond to a PARP inhibitor had partial shrinkage of their tumor with the addition of a kinase inhibitor.
Dr. Marie Bleakley, a pediatric oncology physician-scientist at Fred Hutchinson Cancer Research Center, has received a 2017 Innovative Research Grant in immuno-oncology from Stand Up To Cancer.
New research suggests that some patients with head and neck cancers can benefit by continuing treatment with an immunotherapy drug after their tumors show signs of enlargement according to investigators at Dana-Farber Cancer Institute and other organizations.
What if your body’s ancient defenses against invading bacteria could be hijacked to help kill cancer? In a small sarcoma trial, Fred Hutch scientists led by Dr. Seth Pollack see signs of immune attack after injections of a bacteria-inspired drug.
An Innovative Research Grant from Stand Up to Cancer will help a University of Texas MD Anderson Cancer Center physician scientist and her team understand how the bacteria in the digestive tracts of melanoma patients affects their response to a common immunotherapy drug.
NCCN Imaging AUC™ provide a single access point for all oncology imaging recommendations within the NCCN Guidelines®; currently, NCCN Imaging AUC™ are available for 48 NCCN Guidelines.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right